Comparing Two Treatments for Hepatitis C
Author Information
Author(s): Slim Jihad, Paul Bellafiore, Tempalski Barbara, Rosmarin-DeStefano Corey, Leyden Kevin, Torres Juan, Duprey Sheena, Levaggi Emily
Primary Institution: NYMC, St. Michaels Medical Center, Newark, New Jersey, USA
Hypothesis
Is there a difference in efficacy between glecaprevir/pibrentasvir and sofosbuvir/velpatasvir in treating hepatitis C in a unique care model?
Conclusion
Both treatment regimens showed high completion rates and efficacy without significant differences in outcomes.
Supporting Evidence
- 90.4% of patients completed treatment.
- 8% of patients treated with glecaprevir/pibrentasvir were lost to follow-up compared to 11% for sofosbuvir/velpatasvir.
- Both treatment regimens were well tolerated with no patients discontinuing due to adverse events.
Takeaway
This study looked at two medicines for hepatitis C and found they work just as well when given to people in a special program that helps those with drug problems.
Methodology
This was a prospective observational study comparing the efficacy of two medications in treating hepatitis C among patients in a mobile clinic setting.
Potential Biases
The study may have underestimated adverse events due to reliance on passive patient reporting.
Limitations
The study's generalizability is limited due to its single-center, observational design.
Participant Demographics
The median age of participants was 40 years, with a gender distribution of 63% male and 37% female.
Statistical Information
P-Value
<.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website